JP2013534908A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013534908A5 JP2013534908A5 JP2013511636A JP2013511636A JP2013534908A5 JP 2013534908 A5 JP2013534908 A5 JP 2013534908A5 JP 2013511636 A JP2013511636 A JP 2013511636A JP 2013511636 A JP2013511636 A JP 2013511636A JP 2013534908 A5 JP2013534908 A5 JP 2013534908A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- mir
- nucleic acid
- composition
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10163604 | 2010-05-21 | ||
| EP10163604.1 | 2010-05-21 | ||
| PCT/EP2011/058379 WO2011144761A1 (en) | 2010-05-21 | 2011-05-23 | Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013534908A JP2013534908A (ja) | 2013-09-09 |
| JP2013534908A5 true JP2013534908A5 (enExample) | 2014-07-10 |
| JP5894581B2 JP5894581B2 (ja) | 2016-03-30 |
Family
ID=44537805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013511636A Expired - Fee Related JP5894581B2 (ja) | 2010-05-21 | 2011-05-23 | 骨障害及び／又は心血管障害の治療又は診断に使用する組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20130108687A1 (enExample) |
| EP (1) | EP2571988B1 (enExample) |
| JP (1) | JP5894581B2 (enExample) |
| CN (1) | CN103210085B (enExample) |
| BR (1) | BR112012029656A2 (enExample) |
| CA (1) | CA2800018C (enExample) |
| WO (1) | WO2011144761A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316342A (zh) * | 2013-02-28 | 2013-09-25 | 中国人民解放军沈阳军区总医院 | MiR-31抑制剂用于抑制血管损伤后再狭窄的用途 |
| GB201309882D0 (en) * | 2013-06-03 | 2013-07-17 | Isis Innovation | Prevention and treatment of atrial fibrillation |
| WO2014197747A1 (en) * | 2013-06-05 | 2014-12-11 | The Trustees Of Columbia University In The City Of New York | Exosomes for orofacial diagnostics and therapeutics |
| CN103627705B (zh) * | 2013-10-28 | 2016-02-24 | 南京医科大学 | 与膀胱癌相关的piRNA生物标志物及其应用 |
| US10125398B2 (en) | 2014-06-13 | 2018-11-13 | Universitat Fur Bodenkultur Wien | Compositions and methods for the diagnosis and treatment of bone fractures and disorders |
| WO2016094406A1 (en) * | 2014-12-08 | 2016-06-16 | Thomas Jefferson University | Treatment and prevention of thrombosis using an anti-mir |
| JP6694240B2 (ja) * | 2015-01-30 | 2020-05-13 | ロート製薬株式会社 | 細胞の品質を評価する方法、及び細胞の品質判定キット |
| CN107176976B (zh) * | 2016-03-11 | 2020-02-14 | 上海交通大学医学院 | 微小rna31前体编码多肽在制备免疫调节药物中的应用 |
| CN107151695B (zh) * | 2016-12-08 | 2021-11-09 | 青岛大学 | 用于检测急性心肌缺血疾病的piRNA组合及其检测方法和应用 |
| CN110129429A (zh) * | 2019-05-22 | 2019-08-16 | 昌乐县人民医院 | 核酸分子在制备诊断骨科疾病的产品中的应用 |
| CN110184270A (zh) * | 2019-05-31 | 2019-08-30 | 固安博健生物技术有限公司 | 非编码rna作为男性骨质疏松症的诊断标志物 |
| CN110055256A (zh) * | 2019-05-31 | 2019-07-26 | 固安博健生物技术有限公司 | Loc105376287作为诊断男性骨质疏松症的分子标志物的用途 |
| CN110951869B (zh) * | 2020-01-02 | 2021-06-18 | 北京市创伤骨科研究所 | 骨质疏松诊治用生物标志物 |
| CN111118139B (zh) * | 2020-01-13 | 2021-06-18 | 北京市创伤骨科研究所 | 一种骨质疏松的分子靶标及其应用 |
| CN111599476B (zh) * | 2020-05-15 | 2023-08-11 | 中南大学湘雅医院 | 一种高血压的预测模型及其建立方法以及用于预测高血压的生物标记物 |
| CN112746101B (zh) * | 2020-12-25 | 2023-02-28 | 深圳市人民医院 | 一种骨质疏松诊断标志物及促进骨质疏松骨再生的核酸药物 |
| CN114426950B (zh) * | 2022-01-25 | 2023-08-04 | 北京大学口腔医学院 | 一种高成骨成血管的血清外泌体及其制备方法和应用 |
| WO2025184665A1 (en) * | 2024-03-01 | 2025-09-04 | Immorta Bio, Inc. | Senescence vaccine |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| US5998424A (en) | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
| EP0943684A3 (en) * | 1998-03-10 | 2002-01-23 | Smithkline Beecham Plc | Frizzled-like polypeptides and polynucleotides |
| US7655785B1 (en) * | 2002-11-14 | 2010-02-02 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
| EP1567663A4 (en) * | 2002-12-05 | 2006-04-19 | Univ Arkansas | MOLECULAR DETERMINANTS OF MULTIPLE MYELOMA AND ITS USE |
| TW200418806A (en) | 2003-01-13 | 2004-10-01 | Fujisawa Pharmaceutical Co | HDAC inhibitor |
| AR043507A1 (es) | 2003-03-14 | 2005-08-03 | Lundbeck & Co As H | Derivados de anilina sustituidos y composiciones farmaceuticas |
| WO2005013901A2 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| WO2005079397A2 (en) * | 2004-02-13 | 2005-09-01 | Rockefeller University | Anti-microrna oligonucleotide molecules |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| ES2715625T3 (es) | 2006-04-03 | 2019-06-05 | Roche Innovation Ct Copenhagen As | Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN |
| WO2008013963A2 (en) | 2006-07-28 | 2008-01-31 | University Of Connecticut | Fatty acid amide hydrolase inhibitors |
| US7993831B2 (en) * | 2007-09-14 | 2011-08-09 | Asuragen, Inc. | Methods of normalization in microRNA detection assays |
| WO2010115825A2 (en) | 2009-03-31 | 2010-10-14 | Robert Zimmermann | Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor |
| US20130210883A1 (en) | 2010-05-21 | 2013-08-15 | Johannes Grillari | Lipase inhibitors |
-
2011
- 2011-05-23 CN CN201180034123.1A patent/CN103210085B/zh not_active Expired - Fee Related
- 2011-05-23 US US13/699,272 patent/US20130108687A1/en not_active Abandoned
- 2011-05-23 JP JP2013511636A patent/JP5894581B2/ja not_active Expired - Fee Related
- 2011-05-23 CA CA2800018A patent/CA2800018C/en active Active
- 2011-05-23 BR BR112012029656A patent/BR112012029656A2/pt not_active Application Discontinuation
- 2011-05-23 EP EP11727134.6A patent/EP2571988B1/en active Active
- 2011-05-23 WO PCT/EP2011/058379 patent/WO2011144761A1/en not_active Ceased
-
2013
- 2013-12-02 US US14/094,772 patent/US9150855B2/en not_active Expired - Fee Related
-
2014
- 2014-12-05 US US14/561,585 patent/US9212362B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013534908A5 (enExample) | ||
| AU2012322788B2 (en) | Micrornas in neurodegenerative disorders | |
| Allen et al. | Posttranscriptional mechanisms involving microRNA-27a and b contribute to fast-specific and glucocorticoid-mediated myostatin expression in skeletal muscle | |
| JP5898843B2 (ja) | 血管新生、血管形成、若しくは血管修復を促進するか、又は腫瘍血管新生を阻害する方法 | |
| Cui et al. | MicroRNA-204 regulates vascular smooth muscle cell calcification in vitro and in vivo | |
| AU2014284836B2 (en) | Respiratory disease-related gene specific siRNA, double-helical oligo RNA structure containing siRNA, compositon containing same for preventing or treating respiratory disease | |
| JP2020162610A (ja) | 骨折および骨障害の診断および治療のための組成物および方法 | |
| Fiorillo et al. | Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone | |
| JP6919098B2 (ja) | 筋強直性ジストロフィー１型に対するマイクロｒｎａの変調及びそのためのマイクロｒｎａのアンタゴニスト | |
| WO2009114681A2 (en) | Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy | |
| JP2010539990A (ja) | アンチセンス転写物を標的とするａｇＲＮＡおよびギャップマーを用いた遺伝子発現の調節方法 | |
| Philippen et al. | Antisense MicroRNA therapeutics in cardiovascular disease: quo vadis? | |
| Bengestrate et al. | Genome-wide profiling of microRNAs in adipose mesenchymal stem cell differentiation and mouse models of obesity | |
| WO2009067644A1 (en) | Compositions, systems and methods for obtaining and expanding insulin-producing cells | |
| TW201406774A (zh) | 微ｒｎａ之ｍｉｒ－１５家族之抑制劑 | |
| CN103380215A (zh) | 包含锁定核苷酸的微rna抑制剂 | |
| JP2017528441A5 (enExample) | ||
| KR102547432B1 (ko) | Tut4/7 발현 조절인자를 포함하는 암 예방 또는 치료용 약학적 조성물 | |
| Chang et al. | miR-223 plays a key role in obesogen-enhanced adipogenesis in mesenchymal stem cells and in transgenerational obesity | |
| Gherardi et al. | Transcriptional and epigenetic analyses of the DMD locus reveal novel cis‑acting DNA elements that govern muscle dystrophin expression | |
| JP6928001B2 (ja) | 心臓リモデリングの治療及び診断のためのｌｎｃＲＮＡ Ｍｅｇ３ | |
| WO2018047148A1 (en) | Compounds for the inhibition of mirna | |
| JP2026507051A (ja) | シナプトギリン－３発現を調節するためのオリゴヌクレオチド | |
| WO2014040742A1 (en) | Treatment of heart disease through modulation of hypoxia-induced erna activity | |
| EP3976044A1 (en) | Compounds and methods for inhibiting cancers via rest inhibition |